BioXcel Therapeutics Inc(BTAI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.23 | Insider Own | 2.15% | Shs Outstand | 31.3M | Perf Week | -46.06% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | 20.74% | Insider Trans | -5.57% | Shs Float | 30.6M | Perf Month | -92.04% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | - | Inst Own | 20.13% | Short Float | 10.82% | Perf Quarter | -93.09% |
| Income | -0.07B | P/S | 3.12 | EPS this Y | 52.88% | Inst Trans | -2.67% | Short Ratio | 0.54 | Perf Half Y | -95.23% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -259.62% | Short Interest | 3.31M | Perf YTD | -95.38% |
| Book/sh | -3.69 | P/C | 0.17 | EPS past 3/5Y | 60.75% 37.62% | ROE | - | 52W High | -98.28% ($4.29) | Perf Year | -97.93% |
| Cash/sh | 0.44 | P/FCF | - | Sales past 3/5Y | 19.63% - | ROIC | - | 52W Low | 7.1% ($0.07) | Perf 3Y | -99.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 66.63% | Gross Margin | 22.78% | Volatility(W/M) | 35.2% 18.85% | Perf 5Y | -99.98% |
| Dividend TTM | - | EV/Sales | 125.62 | Sales Y/Y TTM | -14.52% | Oper. Margin | -5970.89% | ATR (14) | 0.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.21 | EPS Q/Q | 80.15% | Profit Margin | -9549.87% | RSI (14) | 20.14 | Recom | 4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.21 | Sales Q/Q | 51.67% | SMA20 | -88.75% ($0.62) | Beta | 0.3 | Target Price | $1 |
| Payout | - | Debt/Eq | - | Earnings | 2026/5/15 | SMA50 | -91.2% ($0.8) | Rel Volume | 0 | Prev Close | $0.07 |
| Employees | 29 | LT Debt/Eq | - | EPS/Sales Surpr. | -1.41% -46% | SMA200 | -94.48% ($1.27) | Avg Volume(3M) | 6.11M | Price | $0.07 |
| IPO | 2018/3/8 | Option/Short | No/No | Trades | 0 | Volume | - | Change | - |
Company
BTAI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧠 This is an AI-driven neuroscience drug development company that holds Igalmi (IGALMI), a treatment for acute agitation symptoms associated with schizophrenia and bipolar disorder. Formulated as a sublingual film for rapid absorption, the dexmedetomidine-based therapy has received FDA approval, and the company is working to expand its indications through broader at-home prescribing and treatment of agitation in Alzheimer's disease.
Over the past 1 year, on the lower side
98% below its 1-year high.
BTAI has weak earning power
-5970.89% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +52.9% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Sell.
Tap to view numbers
Holding long would have lost money
Would have changed by -99.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 20.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $2M.
BTAI $2M PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is BTAI?
BTAI belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BTAI?
The market cap of BTAI is approximately $2M, ranking 5,834 within its sector.
What is the 52-week high and low for BTAI?
BTAI has recorded a 52-week high of $4.29 and a low of $0.07.
